GlassScriptPhysician profile
Fred M Krainin
NPI 1316905177
$8,877.09
in general payments reported to CMS, 2019-2025
30 companies · $28.70 in 2025
The $28.70 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,964 · 2020: $3,041 · 2021: $1,340 · 2022: $469 · 2023: $34.17 · 2025: $28.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $62.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $62.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $5,015.85 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $492.66 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $434.66 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $401.54 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $383.25 | 2019-2022 | |
| Boston Scientific Corporation | $311.44 | 2019-2022 | |
| Pfizer INC. | $218.69 | 2019-2022 | |
| Inari Medical, INC. | $212.00 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $192.58 | 2019-2022 | |
| Edwards Lifesciences Corporation | $163.01 | 2019-2020 | |
| Medtronic, INC. | $145.78 | 2021 | |
| Amgen INC. | $141.47 | 2019-2022 | |
| Chiesi USA, INC. | $122.83 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $98.12 | 2019-2020 | |
| Shockwave Medical, INC | $88.97 | 2022-2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $66.94 | 2019-2020 | |
| Esperion Therapeutics, INC. | $65.38 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $45.30 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.27 | 2020-2021 | |
| Abbott Laboratories | $33.10 | 2021 | |
| Amarin Pharma, INC. | $32.95 | 2020-2021 | |
| Atricure, INC. | $28.70 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Gilead Sciences, INC. | $27.66 | 2019 | |
| Cardinal Health 200 LLC | $26.31 | 2021 | |
| Ge Healthcare | $22.92 | 2020-2021 | |
| Daiichi Sankyo INC. | $15.56 | 2022 | |
| Novo Nordisk INC | $14.32 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $13.49 | 2020 | |
| Alnylam Pharmaceuticals INC. | $11.70 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $8.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fred Krainin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.